By DANIEL BREEN
Researchers at the University of Arkansas for Medical Sciences are studying ways to help protect the heart health of cancer patients from chemotherapy side effects. Dr. Hui-Ming Chang is leading the study, which will be the first Phase 1 cancer clinical trial done at UAMS.
The study aims to limit the heart damage caused by a commonly used chemotherapy drug known as doxorubicin. Chang says the negative effects of the drug sometimes aren’t felt until well after cancer treatment has ended.
Chang’s study involves another drug called dexrazoxane which has been approved by the U.S. Food and Drug Administration to help limit heart damage, but can limit the efficacy of chemotherapy. She says that’s caused dexrazoxane to only be commonly used with very high doses of chemotherapy drugs.
https://www.ualrpublicradio.org/post/uams-announces-first-phase-1-cancer-clinical-trial
Dr. Hui-Ming Chang is leading the study which aims to limit the heart damage caused by a commonly used chemotherapy.
CREDIT UAMS.EDU